Kuwait City, Kuwait
Kuwait City, Kuwait

Time filter

Source Type

Usmani S.,Kuwait Cancer Control Center
Clinical Nuclear Medicine | Year: 2017

ABSTRACT: Bertolotti syndrome is a form of low-back pain associated with lumbosacral transitional vertebrae. We report a case of a 34-year-old woman with breast cancer presented with severe low-back pain. F-NaF PET/CT demonstrates increased radiotracer uptake at the transverse-sacral articulation corresponding to hemisacralized left transverse process of L5 vertebra. Increased tracer uptake in patients with lumbosacral transitional vertebrae seems to correlate with lower-back pain symptoms. F-NaF PET/CT can be useful in evaluation of some uncommon causes of low-back pain. Bertolotti syndrome should always be included in the differential diagnosis of lower-back pain in young patients. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.


Usmani S.,Kuwait Cancer Control Center
Clinical Nuclear Medicine | Year: 2017

ABSTRACT: We report on a 62-year-old man with metastatic prostate cancer (cT3b N1) diagnosed in 2011, treated with total androgen blockage with flutamide and goserelin acetate (Zoladex). He presented with left suprascapular swelling and low-back pain after being asymptomatic for 5 years. His prostate-specific antigen was 0.049 ng/mL. F-NaF PET-CT and Ga-PSMA scan were negative, whereas Ga-DOTA NOC scan done after 10 days showed multiple somatostatin-avid hepatic and lymph node metastasis. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.


VISTA, Calif., May 23, 2017 /PRNewswire/ -- Leica Biosystems announced today that it has struck a key partnership with the Kuwait Ministry of Health, through its distributor, Technical Services Supplies Trading & Contracting Company, W.L.L. The Pathology Council of Kuwait will now adopt Leica Biosystems digital pathology as its standard of care. This initiative will create a nationwide pathology network, powered by Aperio ePathology Solutions, linking eight key hospitals and leveraging pathology expertise across the country. "With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations." The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases. "The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results." *The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States. Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.


"With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations." The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases. "The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results." *The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States. Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.


News Article | May 23, 2017
Site: www.prnewswire.co.uk

"With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations." The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases. "The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results." *The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States. Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.


Zamecnikova A.,Kuwait Cancer Control Center
Expert Review of Hematology | Year: 2010

Many biological and clinical features of chronic myeloid leukemia make it as a paradigm of rational drug design in human cancer. Chronic myeloid leukemia was the first malignancy to be linked to a clear genetic anomaly, the Philadelphia chromosome and, at present, it is probably the best understood of all human malignancies. Studies of the disease pathology revealed that the molecular consequence of the Philadelphia translocation is a BCR-ABL chimeric gene, which encodes a constitutively active tyrosine kinase with wholesale range of biological activities. Animal models have validated the direct role of the BCR-ABL protein in malignant transformation and subsequent research confirmed that its enhanced tyrosine kinase activity is essential and sufficient for the leukemogenesis. The very existence of a single genetic abnormality, presented in essentially all patients with the disease, made it an effective target for molecularly designed therapeutic approaches for the disease. The advent of tyrosine kinase inhibitors, designed specifically to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein, represents one of the major innovations in cancer therapy and may serve as a model for, how discoveries of disease pathogenesis may be translated into the development of successful targeted therapies in cancer medicine. © 2010 Expert Reviews Ltd.


Mohammed E.M.A.,Kuwait Cancer Control Center
Pathogenesis | Year: 2016

Introduction: Multiple sclerosis (MS) is an autoimmune disease that attacks the central nervous system, causing the appearance of focal areas of inflammation and demyelination. A detailed study of MS would offer a better understanding of the causes of increased number of MS cases in the Arab Gulf countries. Materials and Methods: A comprehensive literature search was performed to extract data regarding MS in general and MS in Arabian Gulf countries in specific. Only peer-reviewed, full-text articles published in English were included. Results: Data have shown a noticeable increase in cases of MS in the Arab Gulf countries. Although the underlying causes still remain elusive, many factors have been proposed to influence MS. This review will discuss the factors influencing MS, correlate their effects with disease pathology, their interaction in the context of disease development, and try to explain the increased number of MS in Arabian Gulf countries. Conclusion: Understanding MS development could open new doors for the treatment of MS, as well as initiate novel target therapies for citizens of Arab Gulf countries. © 2016 The Author.


Samir S.M.,Kuwait Cancer Control Center
The Gulf journal of oncology | Year: 2011

Medullary carcinomas of the breast account for fewer than 7% of all invasive breast cancers. Some investigators include medullary carcinomas in the favourable histologic subtype, despite its aggressive histologic appearance. However, others fail to confirm its favourable prognosis. This was a retrospective analysis of sixty-one (61) cases of breast cancer cases diagnosed with Medullary Carcinoma, presenting to the Kuwait Cancer Control Center between 1995 and 2005. Median survival time was 122 months and the seven-year disease free survival was 82%. Overall survival rate was not assessed as no cases died during the study period. No cases were metastatic from the start and only eight cases developed metastases, local recurrence or contralateral breast primary. 68.8% of the cases were Stage I or IIA (i.e. no lymph node affection). There is no overt favourable prognosis of medullary carcinoma when compared to invasive ductal carcinoma. Prognosis is more related to stage than histologic subtyping. The majority of cases were negative estrogen and progesterone receptor status and node negative.


Elbasmi A.,Kuwait Cancer Control Center
The Gulf journal of oncology | Year: 2010

Cancer registry data obtained from the Kuwait Cancer Registry at Kuwait Cancer Control Center (KCCC) of Ministry of Health, State of Kuwait. The data covers the years 1974 to 2007. was to estimate the magnitude of the cancer problem in Kuwait over the period 1974-2007. Age-adjusted incidence rates (ASR) with standard error (er) and 95% confidence intervals (95% CI) of age-standardized rates were estimated. Statistical significance was assessed by examining the standardized rate ratio (SRR). It was noted that by following the Cancer registry data there was a trend of increase in adjusted rates among both males and females. Looking into specific cancers it was noticed that comparing the ASR of colorectal cancer among Kuwaiti males, it increased by about 5 folds over the last 33 years and ranked the 1st most frequent site on the years 2003-2007. Prostate cancer incidence increased by 3 folds (14.5 cases /100,000 populations) and ranked the 4th most frequent site among Kuwaiti males. The incidence of Non Hodgkin's Lymphoma (NHL) and leukemia had increased by 1.5 to 2 folds over the same time period. The rise of lung cancer incidence declined to similar rates compared to that observed in the early 70s and 80s. For Kuwaiti females breast cancer had the highest incidence among Kuwaiti population (15 cases /100,000 populations), it increased by 3 folds (50 cases /100,000 populations) over the last 33 years. The incidence of colorectal cancer increased by about 4 folds; (13 cases /100,000 populations). NHL and leukemia increased by 2-2.5 folds over the same studied duration. Meanwhile Thyroid cancer increased by one fold. Some of the differences in cancer rates over the last 33 years are likely to be attributable to the variation in exposure to specific etiologic factors that are caused by differences in lifestyle and habits, such as dietary, physical activity and obesity. Further research with a view to understanding these changes in cancer incidence is warranted. The need for an interventional prevention programs that vigorously involve, diet, anti-smoking and physical activity among both sexes.


Al-Saleh K.,Kuwait Cancer Control Center
The Gulf journal of oncology | Year: 2012

Proliferating trichilemmal tumors (PTTs) are uncommon exuberant growths of cells derived from the external root sheath. They tend to occur in older women, with a predilection for the scalp. Wide local excision has been the standard treatment. Recent reports have described a rare malignant variant with an aggressive clinical course and a propensity for nodal and distant metastases which, therefore, merits aggressive treatment.

Loading Kuwait Cancer Control Center collaborators
Loading Kuwait Cancer Control Center collaborators